|
| Tuesday, November 26, 2024 |
|
|
Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan |
| The research will be implemented by the Japan Agency forMedical Research and Development (AMED), with NCNP as the lead research institution. more info >> |
|
| Thursday, August 5, 2021 |
|
|
エーザイ、第37回企業広報賞「企業広報大賞」を受賞 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫）は、このたび、一般社団法人日本経済団体連合会（東京都）の関連団体である一般財団法人経済広報センター（東京都、会長：十倉雅和）が主催する第37回企業広報賞において、「企業広報大賞」を受賞しましたのでお知らせします。 more info >> |
|
| Wednesday, November 20, 2024 |
|
|
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan |
| Eisai Co., Ltd. announced today that the amyotrophic lateral sclerosis (ALS) treatment "Rozebalamin for Injection25 mg" (mecobalamin) has been launched in Japan as a treatment for slowing progression of functionalimpairment in amyotrophic lateral sclerosis. more info >> |
|
|
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements |
| Eisai Co., Ltd. announced today that it has launched fibroblast growth factor receptor (FGFR) selective tyrosine kinase inhibitor "TASFYGO Tablets 35mg" (generic name: tasurgratinib succinate) in Japan for the treatment of patients with unresectable biliary tract cancer with FGFR2 gene fusions or rearrangements that progressed after cancer chemotherapy. more info >> |
|
| Friday, November 15, 2024 |
|
|
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment) |
| Eisai Co., Ltd. and Biogen Japan Ltd announced today that a TV commercial will be broadcast nationwide in Japan from November 15 with the aim of increasing public understanding of MCI (Mild Cognitive Impairment). more info >> |
|
|
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease |
| Eisai Co., Ltd. and Biogen Inc. announced today a positive opinion has been received from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending approval of the amyloid-beta (Aβ) monoclonal antibody lecanemab. more info >> |
|
| Tuesday, November 5, 2024 |
|
|
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem" |
| Eisai Co., Ltd. and Eisai's corporate venture capital subsidiary, Eisai Innovation, Inc. announced today that Eisai Innovation,Inc. has been selected as a registered venture capital (Registered VC) of the Strengthening Program for Pharmaceutical Startup Ecosystem implemented by the Japan Agency for Medical Research and Development (AMED). more info >> |
|
| Friday, November 1, 2024 |
|
|
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status |
| Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA). more info >> |
|
| Thursday, October 31, 2024 |
|
|
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference |
| Eisai Co., Ltd. and Biogen Inc. announced today that the latest findings for lecanemab-irmb (U.S. brand name: LEQEMBI(R)), an anti-amyloid beta (Aβ) protofibril* antibody for the treatment of early Alzheimer's disease (AD), were presented at the Clinical Trials for Alzheimer's Disease Conference (CTAD), held in Madrid, Spain, and virtually. more info >> |
|
|
Eisai Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD) |
| Eisai Co. Ltd announced today that the latest findings on anti-MTBR (microtubule binding region) tau antibody E2814 were presented at the 17th annual Clinical Trials on Alzheimer's Disease (CTAD) conference, held in Madrid, Spain, and virtually. more info >> |
|
|
|
|
